Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Qing Zhou; Simon Peter Gampenrieder; Sophie Frantal; Gabriel Rinnerthaler; Christian F Singer; Daniel Egle; Georg Pfeiler; Rupert Bartsch; Viktor Wette; Angelika Pichler; Edgar Petru; Peter C Dubsky; Zsuzsanna Bago-Horvath; Christian Fesl; Margaretha Rudas; Anders Ståhlberg; Ricarda Graf; Sabrina Weber; Nadia Dandachi; Martin Filipits; Michael Gnant; Marija Balic; Ellen Heitzer

doi:10.1158/1078-0432.CCR-21-3231

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Qing Zhou
, Simon Peter Gampenrieder (Co-author)
, Sophie Frantal
, Gabriel Rinnerthaler (Co-author)
, Christian F Singer
, Daniel Egle
, Georg Pfeiler
, Rupert Bartsch
, Viktor Wette
, Angelika Pichler
, Edgar Petru
, Peter C Dubsky
, Zsuzsanna Bago-Horvath
, Christian Fesl
, Margaretha Rudas
, Anders Ståhlberg
, Ricarda Graf
, Sabrina Weber
, Nadia Dandachi
, Martin Filipits

Michael Gnant, Marija Balic, Ellen Heitzer

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

54 Citations (Web of Science)

Original language	English
Pages (from-to)	697-707
Journal	CLINICAL CANCER RESEARCH
Volume	28
Issue number	4
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-3231
Publication status	Published - 2022

Keywords

INFILTRATING LYMPHOCYTES
LIQUID BIOPSY
THERAPY
BURDEN
DNA
CHEMOTHERAPY
RISK

Access to Document

10.1158/1078-0432.CCR-21-3231

Cite this

Zhou, Q., Gampenrieder, S. P., Frantal, S., Rinnerthaler, G., Singer, C. F., Egle, D., Pfeiler, G., Bartsch, R., Wette, V., Pichler, A., Petru, E., Dubsky, P. C., Bago-Horvath, Z., Fesl, C., Rudas, M., Ståhlberg, A., Graf, R., Weber, S., Dandachi, N., ... Heitzer, E. (2022). Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. CLINICAL CANCER RESEARCH , 28(4), 697-707. https://doi.org/10.1158/1078-0432.CCR-21-3231

Zhou, Qing ; Gampenrieder, Simon Peter ; Frantal, Sophie et al. / Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. In: CLINICAL CANCER RESEARCH 2022 ; Vol. 28, No. 4. pp. 697-707.

@article{62279745c26e41f1b97d0e7942b87e76,

title = "Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.",

keywords = "INFILTRATING LYMPHOCYTES, LIQUID BIOPSY, THERAPY, BURDEN, DNA, CHEMOTHERAPY, RISK",

author = "Qing Zhou and Gampenrieder, \{Simon Peter\} and Sophie Frantal and Gabriel Rinnerthaler and Singer, \{Christian F\} and Daniel Egle and Georg Pfeiler and Rupert Bartsch and Viktor Wette and Angelika Pichler and Edgar Petru and Dubsky, \{Peter C\} and Zsuzsanna Bago-Horvath and Christian Fesl and Margaretha Rudas and Anders St{\aa}hlberg and Ricarda Graf and Sabrina Weber and Nadia Dandachi and Martin Filipits and Michael Gnant and Marija Balic and Ellen Heitzer",

note = "Rinnerthaler; Gampenrieder: Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute, Paracelsus Medical University Salzburg",

year = "2022",

doi = "10.1158/1078-0432.CCR-21-3231",

language = "English",

volume = "28",

pages = "697--707",

journal = "CLINICAL CANCER RESEARCH ",

issn = "1078-0432",

publisher = "Amer Assoc Cancer Research",

number = "4",

}

Zhou, Q, Gampenrieder, SP, Frantal, S, Rinnerthaler, G, Singer, CF, Egle, D, Pfeiler, G, Bartsch, R, Wette, V, Pichler, A, Petru, E, Dubsky, PC, Bago-Horvath, Z, Fesl, C, Rudas, M, Ståhlberg, A, Graf, R, Weber, S, Dandachi, N, Filipits, M, Gnant, M, Balic, M & Heitzer, E 2022, 'Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.', CLINICAL CANCER RESEARCH , vol. 28, no. 4, pp. 697-707. https://doi.org/10.1158/1078-0432.CCR-21-3231

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. / Zhou, Qing; Gampenrieder, Simon Peter (Co-author); Frantal, Sophie et al.
In: CLINICAL CANCER RESEARCH , Vol. 28, No. 4, 2022, p. 697-707.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

AU - Zhou, Qing

AU - Gampenrieder, Simon Peter

AU - Frantal, Sophie

AU - Rinnerthaler, Gabriel

AU - Singer, Christian F

AU - Egle, Daniel

AU - Pfeiler, Georg

AU - Bartsch, Rupert

AU - Wette, Viktor

AU - Pichler, Angelika

AU - Petru, Edgar

AU - Dubsky, Peter C

AU - Bago-Horvath, Zsuzsanna

AU - Fesl, Christian

AU - Rudas, Margaretha

AU - Ståhlberg, Anders

AU - Graf, Ricarda

AU - Weber, Sabrina

AU - Dandachi, Nadia

AU - Filipits, Martin

AU - Gnant, Michael

AU - Balic, Marija

AU - Heitzer, Ellen

N1 - Rinnerthaler; Gampenrieder: Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute, Paracelsus Medical University Salzburg

PY - 2022

Y1 - 2022

KW - INFILTRATING LYMPHOCYTES

KW - LIQUID BIOPSY

KW - THERAPY

KW - BURDEN

KW - DNA

KW - CHEMOTHERAPY

KW - RISK

U2 - 10.1158/1078-0432.CCR-21-3231

DO - 10.1158/1078-0432.CCR-21-3231

M3 - Original Article

C2 - 34862246

SN - 1078-0432

VL - 28

SP - 697

EP - 707

JO - CLINICAL CANCER RESEARCH

JF - CLINICAL CANCER RESEARCH

IS - 4

ER -

Zhou Q, Gampenrieder SP, Frantal S, Rinnerthaler G, Singer CF, Egle D et al. Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. CLINICAL CANCER RESEARCH . 2022;28(4):697-707. doi: 10.1158/1078-0432.CCR-21-3231